GRTXGalera Therapeutics, Inc.

About Galera Therapeutics, Inc. (GRTX)

Galera Therapeutics, Inc. (GRTX) is a Biotechnology company headquartered in Malvern, PA, United States whose shares trade over-the-counter on the Pink tier.

Galera Therapeutics, Inc. is a biopharmaceutical company that was historically focused on developing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera's selective dismutase mimetic product candidate avasopasem manganese (avasopasem) was being developed for radiation-induced and cisplatin-related toxicities. The FDA has granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of severe oral mucositis induced by radiotherapy. The Company's second product candidate, rucosopasem manganese (rucosopasem), was being developed to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Rucosopasem has been granted orphan drug designation and orphan medicinal product designation by the FDA and EMA, respectively, for the treatment of pancreatic cancer. Galera is headquartered in Malvern, PA.

GRTX key facts

Ticker symbol

GRTX

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Malvern, PA, United States

Country of incorporation

US

Year of incorporation

2012

Employees

5

Estimated market cap

$1.95M (as of Apr 10, 2025)

Shares outstanding

75,462,390

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Galera Therapeutics, Inc. leadership

• John Mel Sorensen — President, CEO
• Christopher Daniel Degnan — CFO
• Jennifer Evans Stacey — General Counsel, Company Secretary

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with G